Trans-Septal Myocardial Biopsy in Hypertrophic Cardiomyopathy Using the Liwen Procedure: An Introduction of a Novel Technique
Objective. The purpose of this study was to evaluate the feasibility and safety of myocardial biopsy using a new approach, the Liwen procedure. Background. Myocardial biopsy is essential when other methods could not differentiate other etiologies from hypertrophic obstructive cardiomyopathy (HOCM)....
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Journal of Interventional Cardiology |
Online Access: | http://dx.doi.org/10.1155/2021/1905184 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832558900799340544 |
---|---|
author | Chao Han Mengyao Zhou Rui Hu Bo Wang Lei Zuo Jing Li Shengjun Ta David H. Hsi Jiani Liu Lichun Wei Liwen Liu |
author_facet | Chao Han Mengyao Zhou Rui Hu Bo Wang Lei Zuo Jing Li Shengjun Ta David H. Hsi Jiani Liu Lichun Wei Liwen Liu |
author_sort | Chao Han |
collection | DOAJ |
description | Objective. The purpose of this study was to evaluate the feasibility and safety of myocardial biopsy using a new approach, the Liwen procedure. Background. Myocardial biopsy is essential when other methods could not differentiate other etiologies from hypertrophic obstructive cardiomyopathy (HOCM). Our previous work using intramyocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy (Liwen procedure) may provide another approach to obtain the myocardial samples. Method. Seventeen patients with HOCM were enrolled for biopsies through percutaneously accessed intramyocardial septum and evaluated possible complications. Results. We obtained 31 specimens from 17 patients with a success rate of sample acquisition 100.0%. The number of myocardial samples taken per patient was 1.8 ± 0.8, and the average length of all samples was 16.7 ± 5.6 mm which could be used for pathological diagnosis. The complications included pericardial effusion with and without tamponade in one patient (5.9%), and no incidence of nonsustained and sustained ventricular tachycardia, conduction abnormity, perforation, stroke, and pneumothorax. The inhospital and 30-day mortality was 0%. Conclusion. This study has shown that myocardial biopsy of the Liwen procedure is relatively safe and technically feasible with adequate tissue sampling, which may help pathological diagnosis and further research of HOCM of diverse etiologies. This trial is registered with NCT04355260. |
format | Article |
id | doaj-art-dac8044247b64fe5963858564c280cf9 |
institution | Kabale University |
issn | 0896-4327 1540-8183 |
language | English |
publishDate | 2021-01-01 |
publisher | Wiley |
record_format | Article |
series | Journal of Interventional Cardiology |
spelling | doaj-art-dac8044247b64fe5963858564c280cf92025-02-03T01:31:22ZengWileyJournal of Interventional Cardiology0896-43271540-81832021-01-01202110.1155/2021/19051841905184Trans-Septal Myocardial Biopsy in Hypertrophic Cardiomyopathy Using the Liwen Procedure: An Introduction of a Novel TechniqueChao Han0Mengyao Zhou1Rui Hu2Bo Wang3Lei Zuo4Jing Li5Shengjun Ta6David H. Hsi7Jiani Liu8Lichun Wei9Liwen Liu10Department of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaHeart & Vascular Institute, Stamford Hospital, Stamford, CT, USADepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaDepartment of Radiation Oncology, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi’an, Shannxi, ChinaObjective. The purpose of this study was to evaluate the feasibility and safety of myocardial biopsy using a new approach, the Liwen procedure. Background. Myocardial biopsy is essential when other methods could not differentiate other etiologies from hypertrophic obstructive cardiomyopathy (HOCM). Our previous work using intramyocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy (Liwen procedure) may provide another approach to obtain the myocardial samples. Method. Seventeen patients with HOCM were enrolled for biopsies through percutaneously accessed intramyocardial septum and evaluated possible complications. Results. We obtained 31 specimens from 17 patients with a success rate of sample acquisition 100.0%. The number of myocardial samples taken per patient was 1.8 ± 0.8, and the average length of all samples was 16.7 ± 5.6 mm which could be used for pathological diagnosis. The complications included pericardial effusion with and without tamponade in one patient (5.9%), and no incidence of nonsustained and sustained ventricular tachycardia, conduction abnormity, perforation, stroke, and pneumothorax. The inhospital and 30-day mortality was 0%. Conclusion. This study has shown that myocardial biopsy of the Liwen procedure is relatively safe and technically feasible with adequate tissue sampling, which may help pathological diagnosis and further research of HOCM of diverse etiologies. This trial is registered with NCT04355260.http://dx.doi.org/10.1155/2021/1905184 |
spellingShingle | Chao Han Mengyao Zhou Rui Hu Bo Wang Lei Zuo Jing Li Shengjun Ta David H. Hsi Jiani Liu Lichun Wei Liwen Liu Trans-Septal Myocardial Biopsy in Hypertrophic Cardiomyopathy Using the Liwen Procedure: An Introduction of a Novel Technique Journal of Interventional Cardiology |
title | Trans-Septal Myocardial Biopsy in Hypertrophic Cardiomyopathy Using the Liwen Procedure: An Introduction of a Novel Technique |
title_full | Trans-Septal Myocardial Biopsy in Hypertrophic Cardiomyopathy Using the Liwen Procedure: An Introduction of a Novel Technique |
title_fullStr | Trans-Septal Myocardial Biopsy in Hypertrophic Cardiomyopathy Using the Liwen Procedure: An Introduction of a Novel Technique |
title_full_unstemmed | Trans-Septal Myocardial Biopsy in Hypertrophic Cardiomyopathy Using the Liwen Procedure: An Introduction of a Novel Technique |
title_short | Trans-Septal Myocardial Biopsy in Hypertrophic Cardiomyopathy Using the Liwen Procedure: An Introduction of a Novel Technique |
title_sort | trans septal myocardial biopsy in hypertrophic cardiomyopathy using the liwen procedure an introduction of a novel technique |
url | http://dx.doi.org/10.1155/2021/1905184 |
work_keys_str_mv | AT chaohan transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT mengyaozhou transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT ruihu transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT bowang transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT leizuo transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT jingli transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT shengjunta transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT davidhhsi transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT jianiliu transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT lichunwei transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique AT liwenliu transseptalmyocardialbiopsyinhypertrophiccardiomyopathyusingtheliwenprocedureanintroductionofanoveltechnique |